Here's a concise, retail-friendly summary: **1. Business Performance:** Hikal roared back in Q3 FY26!

Consolidated revenue jumped to ₹494 Cr, a 55% QoQ surge, with EBITDA at ₹83 Cr.

The Pharma segment revenue hit ₹337 Cr, leading the recovery as regulatory issues are mostly addressed and supplies resume.

Crop Protection contributed ₹157 Cr, growing sequentially despite market challenges. **2. Growth Drivers or Strategy:** Growth is fueled by strategic moves: new High Potency labs and a pilot plant enhance its CDMO capabilities, especially in Oncology.

Geographic expansion for Pharma and diversification into Personal Care/Specialty Chemicals (expected to commercialize in FY27) are key drivers. **3. Recent Developments:** The Animal Health business has also moved into commercial volumes. **4. Key Financial Metrics:** Q3's net loss of ₹6 Cr was due to a one-time ₹38 Cr exceptional charge for a new labor code (PBT before this was ₹29 Cr). The debt-equity ratio improved to 0.58x. **5. Management Commentary / Outlook:** Management sees Q3 as a turning point, with strong quality systems in place.

They expect continued momentum into Q4, laying a solid foundation for a stronger FY27 driven by a robust order pipeline and stable costs.